Incidence and predisposing factors for de novo post-COVID-19 irritable bowel syndrome

Siyal, Mehreen; Abbas, Zaigham; Ashraf, Javeria; Qadeer, Muhammad Ali; Altaf, Abeer

doi:10.1097/meg.0000000000002475

Cited by 9 publications

(11 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our meta-analysis found that there were some predisposing factors for IBS following SARS-CoV-2 infection including depression or anxiety, PCT. Some studies found that moderate to severe patients with COVID-19 tend to have more GI manifestations and IBS [19,21,22,28]. But our study found that disease activity was not associated with IBS following SARS-CoV-2 infection.…”

Section: Discussioncontrasting

confidence: 86%

“…Patients with IBS have a three-fold increased odd of either anxiety or depression, compared to healthy subjects. Some studies found that oxygen therapy during hospital stay was found to be positively correlated with the development of IBS following SARS-CoV-2 infection [3,28]. Oxygen therapy in SARS-CoV-2 infection depicts significant inflammation and keeping in mind the fact that ACE2 receptors are also present on GI epithelial cells, such intestinal inflammation can lead to long-term GI manifestations [52].…”

Section: Discussionmentioning

confidence: 99%

“…Forty-eight studies were excluded in the first screening because of duplication. After reading the titles, abstracts and full text of citations, 25 studies were excluded and 10 studies were included [16][17][18][19][20][21][22][23][24][25][26][27][28][29]. The PRISMA flow chart is shown in Fig.…”

Section: Study Selection and Baseline Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

Wang,

Zhou,

Huang

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Background: Irritable bowel syndrome (IBS) is a common functional gastrointestinal (GI) disorder. Several studies have analyzed the long-term GI symptoms and IBS following coronavirus disease 2019 (COVID-19). The purpose of this study is to evaluate the incidence and predisposing factors for IBS following COVID-19 by a systematic review and meta-analysis. Methods: Electronic databases were searched to identify relevant studies. Primary outcomes were the pooled incidence rate of IBS following COVID-19 and the pooled relative risk (RR) for IBS in the COVID-19 group compared to the non-COVID-19 group. Secondary outcomes were the pooled RR and the standardized mean difference (SMD) for predisposing factors in the IBS group compared to the non-IBS group. Heterogeneity was evaluated using Cochran’s Q test and I 2 statistics. Results: Ten studies were included in this study. The pooled incidence rate of IBS in COVID-19 patients was 12%. The pooled incidence rate of IBS-D, IBS-C and IBS-M was 5%, 2% and 1%. The pooled incidence rate of IBS in 6 and 12 months was 10% and 3%. The pooled RR for IBS in COVID-19 patients was 1.23 [95% confidence interval (CI) = 0.50–3.01] compared to non-COVID-19 patients. The pooled RR or SMD for mild, moderate, and severe disease activity, procalcitonin (PCT), depression or anxiety in IBS patients following COVID-19 was 0.94 (95% CI = 0.74–1.21), 1.19 (95% CI = 0.65–2.21), 1.30 (95% CI = 0.63–2.66), 6.73 (95% CI = 6.08–7.38) and 3.21 (95% CI = 1.79–5.75). Conclusion: The incidence of IBS following COVID-19 was 12%. But it was not higher than the general population. We also found some predisposing factors for IBS including depression or anxiety, PCT.

show abstract

Section: Discussioncontrasting

confidence: 86%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

Wang,

Zhou,

Huang

et al. 2023

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…Similar to noninfectious IBS, the risk is higher in female patients. The presence of severe disease markers, such as an oxygen requirement and high procalcitonin levels, increases the risk of post-COVID-19 IBS[ 49 ]. Another similar study reported that patients with dyspnea at time of admission and a history of allergies and chronic treatment with proton pump inhibitors had an increased risk of developing post-COVID-19 IBS[ 50 ].…”

Section: Pi-ibs General Datamentioning

confidence: 99%

Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review

Lupu¹,

Ghiciuc²,

Ştefănescu³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Post-infectious irritable bowel syndrome (PI-IBS) is a particular type of IBS, with symptom onset after an acute episode of infectious gastroenteritis. Despite infectious disease resolution and clearance of the inciting pathogen agent, 10% of patients will develop PI-IBS. In susceptible individuals, the exposure to pathogenic organisms leads to a marked shift in the gut microbiota with prolonged changes in host-microbiota interactions. These changes can affect the gut-brain axis and the visceral sensitivity, disrupting the intestinal barrier, altering neuromuscular function, triggering persistent low inflammation, and sustaining the onset of IBS symptoms. There is no specific treatment strategy for PI-IBS. Different drug classes can be used to treat PI-IBS similar to patients with IBS in general, guided by their clinical symptoms. This review summarizes the current evidence for microbial dysbiosis in PI-IBS and analyzes the available data regarding the role of the microbiome in mediating the central and peripheral dysfunctions that lead to IBS symptoms. It also discusses the current state of evidence on therapies targeting the microbiome in the management of PI-IBS. The results of microbial modulation strategies used in relieving IBS symptomatology are encouraging. Several studies on PI-IBS animal models reported promising results. However, published data that describe the efficacy and safety of microbial targeted therapy in PI-IBS patients are scarce. Future research is required.

show abstract

“…The long-term gastrointestinal (GI) consequences are less common chronic morbidities following COVID-19. However, the development of disorders of gut–brain interaction (DGBI), formerly called functional GI disorders (FGID), has been hypothesized and reported following COVID-19 (Table 1) [2 ▪▪ ,3 ▪▪ ,4,5,6,7 ▪▪ ,8–14]. In this paper, we will review the literature on post-COVID-19 DGBI…”

Section: Introductionmentioning

confidence: 99%

Gastrointestinal involvement in post-acute Coronavirus disease (COVID)-19 syndrome

Ghoshal,

Ghoshal

2023

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Ten percentage of patients with coronavirus disease (COVID)-19 report having gastrointestinal (GI) symptoms as severe acute respiratory syndrome coronavirus-2 (SARS-CoV2) not only infects the pulmonary but also the GI tract. GI infections including that due to viral infection is known to cause postinfection disorders of gut–brain interaction (DGBI); hence, we wish to review the long-term GI consequences following COVID-19, particularly post-COVID-19 DGBI. Recent findings At least 12 cohort studies, four of which also included controls documented the occurrence of post-COVID-19 DGBI, particularly IBS following COVID-19. The risk factors for post-COVID-19 DGBI included female gender, symptomatic COVID-19, particularly GI symptoms, the severity of COVID-19, the occurrence of anosmia and ageusia, use of antibiotics and hospitalization during the acute illness, persistent GI symptoms beyond 1 month after recovery, presence of mental health factors, The putative mechanisms for post-COVID-19 DGBI include altered gut motility, visceral hypersensitivity, gut microbiota dysbiosis, GI inflammation, and immune activation, changes in intestinal permeability, and alterations in the enteroendocrine system and serotonin metabolism. Summary Long-term sequelae of SARS-CoV2 infection may persist even after recovery from COVID-19. Patients with COVID-19 are more likely to develop post-COVID-19 IBS than healthy controls. Post-COVID-19 IBS may pose a substantial healthcare burden to society.

show abstract

Incidence and predisposing factors for de novo post-COVID-19 irritable bowel syndrome

Cited by 9 publications

References 29 publications

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

The incidence and predisposing factors for irritable bowel syndrome following COVID-19: a systematic review and meta-analysis

Emerging role of the gut microbiome in post-infectious irritable bowel syndrome: A literature review

Gastrointestinal involvement in post-acute Coronavirus disease (COVID)-19 syndrome

Contact Info

Product

Resources

About